Trump's Advisory Board Suggests National Academies Panel Lead Rx Value-Based Efforts

The National Academies of Sciences, Engineering, and Medicine should convene a committee to review schemes for determining the value of cancer drugs, a presidential cancer advisory panel recommended Tuesday (March 13). The Institute for Clinical and Economic Review (ICER) and the Memorial Sloan Kettering Drug Pricing Lab have value frameworks, but drug makers often push back against those approaches and there is no broadly accepted approach to determining the value of drugs. The report by the president's cancer panel includes...